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ABSTRACT Psoriasis management can be challenging, complicated sometimes by 
being associated with other systematic inflammatory diseases including metabolic 
syndrome, myocardial infarction, hypertension, obesity, diabetes mellitus, and hy-
perlipidemia. Of particularly concern is its cardiovascular linkage. It is noteworthy 
and reassuring that some therapeutic options for psoriasis may be cardio-protec-
tive. We highlight phototherapy, methotrexate, and TNF alpha inhibitors and other 
biological agents for psoriasis that may lower the risk of cardiovascular events. Ways 
to reduce cardiovascular risk in patients with psoriasis should be encouraged. We 
concur with the conclusion that long-term study is necessary to assess the risks 
and benefits of biologic therapy, but that persons with preexistent cardiovascular 
disease or at high risk for it might benefit from medication with cardio-preventive 
value.
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InTRODuCTIOn
Psoriasis is a systematic chronic inflammatory 
autoimmune disease (1). It had been deemed as a 
keratinocyte dysfunction disorder, later as an im-
munologic disease, more recently as an interleukin 
(IL)-12/Th1-mediated process, and now as an IL-23/
Th17-mediated condition, with multiple therapeutic 
approaches targeting IL-12/IL-23, IL-23, IL-17, and IL-
17R. As an interleukin (IL)-12/Th1-mediated disease, 
therapy options include anti-CD2, anti-CD11a, and 
tumor necrosis factor-alpha blockers.
Common psoriasis can be viewed as more than 
a skin disorder (2). The disease process has been as-
sociated with many other systematic inflammatory 
diseases, including but not limited to arthritis, meta-
bolic syndrome, myocardial infarction, hypertension, 
diabetes mellitus, and hyperlipidemia (2-4). For every 
10% increase in body surface area for patients with 
psoriasis, there was an approximately 20% higher 
hazard of diabetes (5). This association is not only 
limited to adults, but to the pediatric population as 
well. In a study from the Nationwide Inpatient Sam-
ple, pediatric psoriasis was significantly associated 
with obesity, hypertension, diabetes, and arrhythmia 
(6). The cardiovascular system linked with psoriasis is 
of particular importance due to increased morbidity 
and mortality (7). There have been studies showcas-
ing the effects of TNF alpha inhibitors, methotrexate, 
and other biological agents reducing the risk of car-
diovascular events in patients with psoriasis (8-11). 
The inhibition of the inflammatory process from these 
drugs protects the heart from damage, reducing in-
flammatory changes of the epithelial tissue (2,12). We 
review the cardio-protective properties of commonly 
used drugs for treatment of psoriasis. Although rec-
ommending psoriasis therapy solely based on car-
diovascular impact is probably unwise, for systemic 
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therapy with cardiovascular disease or a high risk of it, 
TNF alpha inhibitors and methotrexate offer the best 
evidence of benefit (2,8,10,11).
Pathogenesis of cardiovascular effects 
due to psoriasis 
The process of the systematic inflammation from 
psoriasis is complex. Psoriasis has been associated 
with numerous cardiovascular problems including 
coronary atheromas, atherogenesis, increased coag-
ulation, atheromatous plaques, and systolic/diastolic 
dysfunction as shown in Table 1. T-helper cells include 
Th1, Th2, and Th17 cells, the latter secreting the pro-
inflammatory cytokine interleukin-17A, which helps 
recruit neutrophils. IL-23 induces the differentiation 
of naive CD4+ T-cells into Th17 cells that produce IL-
17, IL-17F, IL-6, and TNF-α  (13,14). Furue et al. (13) sug-
gested that the initial trigger of psoriasis is due to the 
activation of plasmacytoid dendritic cells, which are 
stimulated from damaged keratinocytes by the host 
DNA and antimicrobial peptide LL-37 (15-17). The 
activated plasmacytoid dendritic cells produce TNF-
alpha, IL-12, and IL-23, whereas IL-23 activates IL-17 
producing effector cells. These cells produce IL-17A 
which bind to receptor IL-17, which downregulates 
the differentiation of keratinocytes and upregulates 
its proliferation, including recruiting neutrophils in 
the inflammatory process (13). A pivotal factor is the 
accumulation of proinflammatory cytokines such as 
TNF-alpha, which induces systematic inflammation 
and ultimately systematic diseases including cardio-
vascular diseases, type 2 diabetes mellitus, and obesi-
ty (13). Mehta et al. found that 76.9% of the 438 genes 
increased in psoriasis were also elevated in advanced 
stage atherosclerotic plaques, and the gene set was 
disproportionately induced by IFN-gamma and TNF-
alpha (14). In the same study, INF-gamma and TNF-al-
pha receptors were increased in coronary atheromas 
compared with healthy coronary vascular tissue, and 
circulating TNF-alpha and INF-gamma were higher in 
the serum of patients with psoriasis. INF-gamma and 
TNF-alpha are thought to induce a pro-inflammatory 
response in endothelial and atherosclerotic tissues 
and could be a possible mechanism due to which pa-
tients with psoriasis have a higher incidence of car-
diovascular disease (18-25).
In addition, homocysteine and endocan may play 
a role in cardiovascular diseases and act as biomark-
ers (26). High levels of homocysteine increase oxida-
tive stress, cause endothelial dysfunction and athero-
genesis, and activate the coagulation cascade (27,28). 
Increasing levels of serum homocysteine correlate 
with disease severity but not with duration of psoria-
sis (29,30). However, Ozden et al. (26) showed no cor-
relation with disease severity or duration. Therefore, 
the homocysteine serum concentration could be an 
independent risk factor for the assessment of cardio-
vascular risk. Endocan stimulates the proliferation 
and migration of vascular smooth muscle cells, which 
increases the development of atheromatous plaques 
(26,31). Endocan may act as a potential biomarker for 
disease severity and duration based on the concen-
tration (26,32). Ozden et al. and Orem et al. showed a 
significant association between left ventricular asyn-
chrony in patients with psoriasis compared with con-
trols, and the Tei index, which measures both global 
systolic and diastolic function, was also significantly 
higher for patients with psoriasis, possibly due to in-
creased inflammation through cytokine stimulating 
keratinocyte proliferation and/or secondary amyloid 
deposition (26,33). Both these parameters could be 
used for future findings in patients with psoriasis to 
determine cardiac involvement.  
Methotrexate and psoriasis-related  
cardiovascular effects 
Methotrexate is a folate analogue commonly used 
for the treatment of psoriasis. Its effects lower inflam-
mation and hyperhomocysteinemia, which are both 
potential causes of the cardiovascular diseases asso-
ciated with psoriasis (1,18). Methotrexate has been 
found to reduce the incidence of cardiovascular-re-
lated diseases in patients with psoriasis. In a study 
performed with 7,615 American military veterans 
with psoriasis, those prescribed methotrexate were 
Table 1. Cardiovascular problems associated with psoriasis
CARDIOvASCULAR PROBLEM MECHANISM 
Coronary atheroma Increased levels of TNF-alpha and INF-gamma 
Atherogenesis Increased levels of homocysteine 
Increased coagulation Increased levels of homocysteine
Atheromatous plaques Increased levels of endocan 
Systolic/Diastolic dysfunction Increased cytokines and/or amyloid deposition
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Table 2. Medications and psoriasis
MEDICATION MECHANISM RESULTS FROM STUDIES
Methotrexate Folate analogue lowering 
inflammation and 
hyperhomocysteinemia  
RR 0.73 in reduced incidences of cardio-related diseases 
compared with not taking methotrexate (18)
OR 0.45 in reduced rate of MI compared with topical 
treatment (2)
OR 0.73 in patients with RA and psoriasis for 
cardiovascular events (19)  
TNF-alpha inhibitors Inhibits TNF-alpha which 
decreases levels of inflammation  
Significant reduction of carotid intima-media thickness 
from 0.70 to 0.63 (22)
RR 0.45 in MI incidence compared with topical cohort 
(43)
0.55 HR for major cardiovascular events compared with 
methotrexate cohort (7)
Adjusted β coefficient -2.09 for decreased atherosclerosis 
progression in men (42) 
IL-23 and IL-17 inhibitors  Antibodies against 
immunoglobulins associated with 
inflammation 
No known studies featuring cardio-protective effects 
Phototherapy  Alteration of cytokine profile, 
induction of cellular apoptosis, 
immunosuppression promotion 
and downregulation of IL-17
Significant resistin levels from 9.02+/-8.83 ng/mL to 
4.86+/-3.30 ng/mL (39)
TNF-alpha levels were significantly reduced from 1.60 to 
1.30 for PUvA and 1.10 to 0.80 for NBUvB and CRP levels 
were significantly reduced from 3.90 to 2.59 for PUvA 
and 2.35 to 2.32 for NBUvB (35)
RR: Relative risk; OR: Odds ratio; HR: Hazards ratio; MI: Myocardial infarction; RA: Rheumatoid arthritis
found to have a relative risk of 0.73 compared with 
those who were not taking methotrexate, with a 95% 
CI of 0.55-0.98 (18). In a review of international co-
horts, methotrexate significantly reduced the rate of 
myocardial infarction in patients compared with topi-
cal treatment (OR of 0.45 with a 95% CI of 0.28-0.73) 
(2). In a systematic review and meta-analysis study of 
rheumatoid arthritis and psoriasis, the pooled odds 
ratio was 0.73 with a 95% CI of 0.70-0.77, showing 
a significant decrease in the risk of cardiovascular 
events with methotrexate (19). Another meta-analy-
sis showed methotrexate was associated with a 21% 
lower risk of total cardiovascular disease (95% CI of 
0.73-0.87), although out of the 10 studies only one 
looked at psoriasis and the other nine studied rheu-
matoid arthritis (20). Regardless of the limited num-
ber of studies performed with psoriasis compared 
with rheumatoid arthritis, methotrexate has been 
shown to have cardiovascular protective effects in 
patients with psoriasis.
TnF-alpha inhibitors and psoriasis-related 
cardiovascular effects 
It has been postulated that IFN-γ and TNF-α work 
synergistically in both psoriasis and atherogenesis, 
possibly linking these two processes in some patients 
(34-42). TNF-alpha inhibitors and methotrexate have 
been used for the treatment of psoriasis. TNF-alpha 
is a pro-inflammatory cytokine which stimulates ke-
ratinocyte production and activates dermal macro-
phages and dendritic cells which are thought to be 
imperative to the pathogenesis of psoriasis and car-
diovascular events (13,21). A 2-year study of carotid 
intima-media thickness showed a significant reduc-
tion from 0.70 to 0.63 with patients on long-term TNF-
alpha inhibitors, compared with a significant progres-
sion from 0.79 to 0.82 with patients who were naïve 
to TNF-alpha inhibitors (22). In a retrospective cohort 
study of patients with psoriasis, the incident rates of 
MI for TNF-alpha inhibitors, oral/phototherapy, and 
topical cohorts were 3.05, 3.85, and 6.73 per 1000 pa-
tient-years, respectively (43). The TNF-alpha inhibitor 
cohort had a statistically significant 55% reduction 
(0.45 RR with 95% CI of 0.30-0.68) in MI incidence 
compared with the topical cohort. In a study com-
paring TNF-alpha inhibitors and methotrexate, the 
major cardiovascular events hazard was 45% (0.55 HR 
with a 95% CI of 0.45-0.67), lower for the TNF-alpha 
cohort than for the methotrexate cohort (7). TNF-
alpha inhibitors have also been shown to decrease 
atherosclerosis progression in men; this association 
remained statistically significant (adjusted β coeffi-
cient=-2.09, 95% CI -3.32, to 0.86; P<0.001) even after 
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controlling for cardiovascular risk factors and lipid-
lowering drugs (41). Among men, TNF-alpha inhibi-
tors were also associated with a reduced rate of ath-
erosclerosis progression compared with non-biologic 
anti-psoriasis medications and compared with no sys-
temic anti-psoriatic therapy (41). However, TNF-alpha 
inhibitors are well-known risk factors for heart failure, 
especially infliximab, which has been shown to in-
crease hospitalizations, morbidity, and mortality (42). 
IL-23 and IL-17 inhibitors and psoriasis 
The IL-23/Th17-mediated disorder known as psori-
asis has been treated with several novel drugs target-
ing IL-12/IL-23, IL-23, IL-17, and IL-17R. Inhibiting IL-23 
and IL-17 is one approach (13,23). The first medica-
tion approved by the Food and Drug Administration 
(FDA) and most commonly employed is ustekinum-
ab, a monoclonal antibody directed against IL-23 and 
IL-12 (23). Three IL-17 antagonist drugs (secukinum-
ab, ixekizumab, and brodalumab) were recently ap-
proved for treatment of psoriatic diseases (24). Com-
mon side-effects associated with these medications 
include upper respiratory infections, headache, pain, 
and nasopharyngitis (23,24). Myocardial and cerebral 
infarctions were observed in patients during the clini-
cal trials of ustekinumab, although they were limited 
to 2 events and 1 event, respectively (23). In a clinical 
trial follow-up with ustekinumab, cumulative rates of 
0.56 and 0.46 adverse cardiovascular events per 100-
patient years were reported in patients treated with 
45 mg and 90 mg, respectively. These results were 
consistent with those in the general and psoriasis 
populations (25). However, to our knowledge there 
have not been any studies on cardio-protection re-
garding these biological agents, unlike methotrexate 
and TNF-alpha inhibitors. 
Phototherapy and psoriasis 
As psoriasis is an inflammation-mediated disease, 
it is associated with a number of markers of inflam-
mation, including C-reactive protein, IL-6, and homo-
cysteine (34). In addition, psoriasis has been associat-
ed with insulin resistance, and elevation of leptin and 
resistin, which act as biomarkers, has been reported 
(2,35). Phototherapy is a good treatment option for 
psoriasis. Its mechanism of action for treatment has 
been associated with its alteration of the cytokine 
profile, induction of cellular apoptosis, and immuno-
suppression promotion as well as the downregula-
tion of the IL-17 pathway (36,37). In a study with 50 
subjects with psoriasis, a significant decrease in the 
number of subjects who met the IDF metabolic syn-
drome criteria was documented after treatment with 
narrow-band UvB (NB-UvB) (38). Another study dem-
onstrated a significant decrease (P<0.001) in resistin 
levels after bath PUvA or NB-UvB from 9.02+/-8.83 
ng/mL to 4.86+/-3.30 ng/mL (39). In addition, it docu-
mented a correlation between decreased resistin lev-
els and the Psoriatic Area Severity Index (PASI) score, 
suggesting that the phototherapy and resistin lev-
els are clinically relevant (39). In a prospective study 
comparing topical therapy with calcipotriol and be-
tamethasone dipropionate versus NB-UvB and PUvA, 
NB-UvB showed a significant reduction in TNF-alpha 
and CRP, while PUvA also showed a significant reduc-
tion not only in the same biomarkers, but also in IL-6 
and a significant increase in adiponectin, a protein in-
volved in fatty acid breakdown (35). Phototherapy in-
creases vitamin D, which can lead to better insulin se-
cretion and sensitivity (34). However, the relevance of 
vitamin D in psoriasis is debatable; further evidence 
should be pursued regarding the value of vitamin D 
supplementation (40) (Table 2). 
COnCLuSIOn
Based on a number of studies involving metho-
trexate and TNF-alpha inhibitors, these medica-
tions appear to provide cardio-protective effects for 
patients with psoriasis. Therefore, they should be 
considered with patients who have cardiovascular 
comorbidities along with psoriasis. Evaluation of an-
tibody inhibitors of IL-23 and IL-17 should be com-
pared with methotrexate and TNF-alpha inhibitors in 
terms of heart-related effects. More studies should be 
pursued regarding these novel biological agents and 
their effects on the cardiovascular system. 
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